Brief: NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for NRX-101
18/12/2023 11:52
Dec 18 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF ITS
INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR NRX-101 IN THE
TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS
* NRX PHARMACEUTICALS INC- AWAITS FDA'S RESPONSE TO ITS
REQUEST
FOR QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) DESIGNATION,
EXPECTED NEXT MONTH
Source text for Eikon: ID:nPn8WWmmRa
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview